Patents by Inventor Julia A. Hopkins

Julia A. Hopkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mitochondrial DNA prostate cancer marker and related systems and methods
    Patent number: 11499195
    Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of the patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 15, 2022
    Assignees: Ontario Institute for Cancer Research, University Health Network
    Inventors: Julia A. Hopkins, Paul Boutros, Robert G. Bristow
  • MITOCHONDRIAL DNA PROSTATE CANCER MARKER AND RELATED SYSTEMS AND METHODS
    Publication number: 20190112672
    Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.
    Type: Application
    Filed: June 2, 2017
    Publication date: April 18, 2019
    Inventors: Julia A. Hopkins, Paul Boutros, Robert G. Bristow